Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Autoantibody Stories

2010-07-15 13:25:10

 Two UNC School of Medicine faculty authored an editorial in the July 15, 2010 New England Journal of Medicine commenting on results from two clinical trials using the drug Rituximab to treat small-vessel vasculitis, a rare autoimmune disease. The trials took place in the United States "“ Rituximab in ANCA-Associated Vasculitis (RAVE) -- and in Europe -- Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis (RITUXIVAS). Both trials showed that rituximab was...

2010-06-15 00:25:19

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it. Also Silvia Bosello, Maria De Santis, Gina Lama, Cristina Spanò, Cristiana Angelucci,...

2010-05-14 08:56:00

NEW BRUNSWICK, N.J., May 14 /PRNewswire-USNewswire/ -- As many as 5.3 million Americans, and 35 million people worldwide, are living with Alzheimer's disease (AD), a devastating neurodegenerative illness characterized by memory loss, cognitive decline and widespread destruction of neurons in the brain. Today, there is no definitive diagnosis for the disease, and no treatment to cure it. AD is the most common form of dementia and, with our aging population, the number of people who will...

2010-04-19 08:00:00

NOVATO, Calif., April 19 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Firdapse(TM) (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010. Firdapse received marketing approval in the...

2010-03-02 08:15:00

DENVER, March 2 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format. The new format offers high-volume testing labs the same performance as the currently available Corgenix rapid assay with improved efficiency and high-volume analysis. "Offering both extended and short assay formats allows us to maintain...

2010-02-25 09:57:45

Study finds SLE patients at risk for developing atherosclerosis A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease. This increase in anti-apolipoprotein (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP) may contribute to the development of atherosclerosis in SLE patients, placing them at risk for...

2010-02-01 12:16:43

Two studies published online on February 1 in the Journal of Experimental Medicine (www.jem.org) reveal that patients with a rare autoimmune disease produce antibodies that attack microbe-fighting immune proteins called cytokines. These findings may help explain why these patients suffer recurrent yeast infections. Autoimmune polyendocrine syndrome, or APS-I, afflicts one in 100,000 people and is characterized by disrupted thyroid and adrenal gland function and recurrent skin infections with...

2010-01-05 15:00:00

NOVATO, Calif., Jan. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Amifampridine phosphate, developed by the pharmaceutical unit (AGEPS) of the Paris Public Hospital Authority (AP-HP) and licensed from EUSA Pharma SAS, is the first approved treatment for LEMS,...

2009-07-30 23:51:39

Sunlight may be associated with the development of certain autoimmune diseases, particularly in women, U.S. researchers said. Researchers at the National Institute of Environmental Health Sciences, part of the National Institutes of Health, said women are more likely than men to develop many autoimmune diseases, but the reasons for this have not been clear. We only found the association between ultraviolet radiation exposure and dermatomyositis -- a connective-tissue disease characterized by...

2009-07-30 12:48:49

Ultraviolet (UV) radiation from sunlight may be associated with the development of certain autoimmune diseases, particularly in women, according to a study by researchers at the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health."This study found that women who lived in areas with higher levels of UV exposure when they developed an autoimmune muscle disease called myositis were more likely to develop the form known as dermatomyositis, which...